Assays for determining levels of plasma protease C1 inhibitor

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10690670
APP PUB NO 20150362492A1
SERIAL NO

14761671

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides assay methods of detecting plasma protease CI inhibitor (Cl-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • DYAX CORP.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Joseph, Kusumam Mt. Pleasant, US 3 23
Kaplan, Allen P Charleston, US 6 63

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Dec 23, 2023
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 23, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 23, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00